Caribou Biosciences CRBU Stock
Caribou Biosciences Price Chart
Caribou Biosciences CRBU Financial and Trading Overview
Caribou Biosciences stock price | 0.77 USD |
Previous Close | 4.63 USD |
Open | 4.58 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 800 |
Day's Range | 4.41 - 4.65 USD |
52 Week Range | 4.05 - 13.19 USD |
Volume | 765.89K USD |
Avg. Volume | 614.22K USD |
Market Cap | 282.27M USD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.65 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 28.43 USD |
CRBU Valuation Measures
Enterprise Value | 83M USD |
Trailing P/E | N/A |
Forward P/E | -1.9491526 |
PEG Ratio (5 yr expected) | 0.22 |
Price/Sales (ttm) | 19.216627 |
Price/Book (mrq) | 1.0136623 |
Enterprise Value/Revenue | 5.65 |
Enterprise Value/EBITDA | -0.723 |
Trading Information
Caribou Biosciences Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -17.11% |
S&P500 52-Week Change | 20.43% |
52 Week High | 13.19 USD |
52 Week Low | 4.05 USD |
50-Day Moving Average | 4.52 USD |
200-Day Moving Average | 7.18 USD |
CRBU Share Statistics
Avg. Volume (3 month) | 614.22K USD |
Avg. Daily Volume (10-Days) | 622.76K USD |
Shares Outstanding | 61.36M |
Float | 50.04M |
Short Ratio | 11.91 |
% Held by Insiders | 10.83% |
% Held by Institutions | 73.19% |
Shares Short | 7.92M |
Short % of Float | 13.83% |
Short % of Shares Outstanding | 12.90% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -794.21% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -18.37% |
Return on Equity (ttm) | -33.34% |
Income Statement
Revenue (ttm) | 14.69M USD |
Revenue Per Share (ttm) | 0.24 USD |
Quarterly Revenue Growth (yoy) | 31.50% |
Gross Profit (ttm) | -68379000 USD |
EBITDA | -114759000 USD |
Net Income Avi to Common (ttm) | -108377000 USD |
Diluted EPS (ttm) | -1.78 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 228.54M USD |
Total Cash Per Share (mrq) | 3.72 USD |
Total Debt (mrq) | 27.42M USD |
Total Debt/Equity (mrq) | 9.86 USD |
Current Ratio (mrq) | 8.837 |
Book Value Per Share (mrq) | 4.538 |
Cash Flow Statement
Operating Cash Flow (ttm) | -97232000 USD |
Levered Free Cash Flow (ttm) | -63986752 USD |
Profile of Caribou Biosciences
Country | United States |
State | CA |
City | Berkeley |
Address | 2929 7th Street |
ZIP | 94710 |
Phone | 510 982 6030 |
Website | https://cariboubio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 137 |
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Q&A For Caribou Biosciences Stock
What is a current CRBU stock price?
Caribou Biosciences CRBU stock price today per share is 0.77 USD.
How to purchase Caribou Biosciences stock?
You can buy CRBU shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Caribou Biosciences?
The stock symbol or ticker of Caribou Biosciences is CRBU.
Which industry does the Caribou Biosciences company belong to?
The Caribou Biosciences industry is Biotechnology.
How many shares does Caribou Biosciences have in circulation?
The max supply of Caribou Biosciences shares is 93M.
What is Caribou Biosciences Price to Earnings Ratio (PE Ratio)?
Caribou Biosciences PE Ratio is now.
What was Caribou Biosciences earnings per share over the trailing 12 months (TTM)?
Caribou Biosciences EPS is -1.65 USD over the trailing 12 months.
Which sector does the Caribou Biosciences company belong to?
The Caribou Biosciences sector is Healthcare.
Caribou Biosciences CRBU included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}